Johnson & Johnson today announced new 96-week data from the long-term extensions (LTE) of the Phase 3 GRAVITI, GALAXI 2 and GALAXI 3 studies, which show the durability of TREMFYA® (guselkumab) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback